Lung Cancer Diagnostics Market to Surpass USD 34.8 Bn by 2034, Led by Roche, Thermo Fisher Scientific, and Abbott Laboratories

The global lung cancer diagnostics market is poised for steady growth, driven by rising cancer prevalence, increasing awareness, and advancements in early detection technologies. Valued at USD 15.1 billion in 2023, the market is projected to expand at a CAGR of 7.9% from 2024 to 2034. By the end of 2034, it is expected to surpass USD 34.8 billion, supported by growing adoption of advanced imaging techniques, biomarker-based testing, and government initiatives focused on improving cancer screening and diagnosis rates worldwide.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74159

Market Overview

Lung cancer is a type of cancer that affects the cells lining the air passages. It is the leading cause of cancer deaths globally, accounting for over 1.7 million deaths each year. The two primary types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Early detection and treatment of lung cancer plays a crucial role in increasing the chances of survival. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy.

The choice of treatment depends on the type and stage of the cancer, as well as the patient's overall health. Various diagnostic tests and technologies are used to detect and diagnose lung cancer. Common diagnostic methods are chest X-ray, CT scan, PET scan, biopsy, and blood test

Analysts' Viewpoint

Increase in incidence of lung cancer, especially in developing countries, is the key driver of the global lung cancer diagnostics market. Surge in awareness about the importance of early and accurate diagnosis of this cancer is expected to accelerate industry development.

Technological advancements in diagnostic technology such as development of non-invasive diagnostic methods and discovery of new biomarkers are anticipated to offer lucrative opportunities to market players.

However, high cost of diagnostic tests is a key lung cancer diagnostics market restraint. Availability of alternative diagnostic methods that are more accessible and cost-effective is also projected to hamper market progress. Manufacturers are investing significantly in R&D activities pertaining to new and improved diagnostic methods to increase their market share.

Analysis of Key Players

The competitive landscape is dominated by diagnostic conglomerates and specialized genomic sequencing firms.

Leading companies operating in the global lung cancer diagnostics market include:

• Abbott
• Bio-Rad Laboratories, Inc.
• Siemens Healthcare
• GE HealthCare
• Amoy Diagnostics Co.
• Boditech Med, Inc.
• Danaher
• F Hoffmann-La Roche
• INOVIQ
• MedGenome
• Quest Diagnostics Incorporated
• DiaSorin S.p.A.
• Oncocyte Corporation
• QIAGEN
• Thermo Fisher Scientific, Inc.
• NanoString Technologies
• Biodesix
• Others Prominent Players

Strategic moves in 2026 show players focusing on "Pathomics-as-a-Service," where deep-learning platforms are integrated directly into digital pathology workflows to predict immunotherapy responses.

Recent Developments (2025–2026)

• In September 2024, Roche announced the expansion of its digital pathology open environment with the integration of more than 20 advanced AI algorithms from eight new collaborators. The strategic collaborations would, therefore, further drive support for pathologists and scientists in driving cancer research and diagnosis at the edge of cutting-edge AI. The seamless integration is made possible by Roche's navify Digital Pathology enterprise software, an application for the pathologist's workflow, which today integrates a wide variety of AI-driven algorithms from it, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights to help benefit cancer patients through precision medicine, enabling treatments to be more targeted.
• In July 2022, The International Atomic Energy Agency (IAEA) announced that it had entered into a partnership with the medical imaging company, GE HealthCare, to train professionals in that field under its Rays of Hope initiative-aimed at addressing global inequity in access to life-saving cancer diagnosis and treatment. It is its first such agreement under Rays of Hope with a private company. Under the one-year partnership with GE HealthCare, radiologists and nuclear medicine professionals from Africa and Latin America will undergo both - in and out of classroom training in diagnostic techniques that help them detect cancer, among the other specific diseases. Such training will generally increase the capacity to conduct diagnoses in low to middle-income countries.
• In November 2022, a licensing and product development agreement was signed by Bio-Rad Laboratories, Inc. and NuProbe USA. As per the agreement, NuProbe USA will grant Bio-Rad an exclusive license to utilize its allele enrichment technologies for the creation of multiplexed digital PCR assays. Bio-Rad's product line in oncology will grow with the use of this technology. In this field, highly sensitive and multiplexed mutation detection assays help with disease monitoring, therapy selection, and translational research.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74159

Key Developments & Trends

• AI-Assisted LDCT: Software that reduces "false positives" in lung nodule screening, improving the diagnostic yield of national programs.
• NGS Expansion: Shift from single-gene testing to comprehensive genomic profiling (CGP) panels that identify hundreds of mutations at once.
• Companion Diagnostics (CDx): Every new targeted therapy (e.g., for KRAS G12D or HER2) is now launched alongside a mandatory biomarker assay.
• Digital Pathology: Transition from physical glass slides to digital pathomics, enabling remote expert consultation and AI-driven analysis.
• DNA Methylation Fingerprinting: Using epigenetic switches to identify tumor tissue of origin and predict treatment resistance.

Challenges

• High Cost of Sequencing: While prices are falling, comprehensive NGS still faces reimbursement hurdles in emerging markets.
• Data Overload: The transition to "multimodal" data creates a bottleneck for pathologists who must interpret complex, multi-source AI insights.
• Lack of Awareness: In several regions, screening is still perceived as "unnecessary" in the absence of symptoms, leading to late-stage diagnoses.
• Sample Quality: Liquid biopsies require high-sensitivity assays to detect low concentrations of circulating tumor DNA (ctDNA) in early-stage patients.

Opportunities

• National Screening Mandates: Governments in East Asia and Europe are rapidly expanding LDCT coverage for high-risk smokers.
• Biosimilars & Generic Targeted Drugs: Driving the need for low-cost, high-volume testing in the APAC region.
• Tele-Diagnostics: Using cloud-based AI platforms to bring high-end diagnostic expertise to rural clinics.
• Minimal Residual Disease (MRD): Longitudinal testing to detect cancer recurrence months before it appears on traditional scans.

Market Segmentation

➤ By Test Type

• Molecular & Genomic Tests (Leading Segment; CAGR 8.2%)
• Imaging (LDCT, PET-CT)
• Biopsy & Sputum Cytology
• Biomarkers (Liquid Biopsy)

➤ By Cancer Type

• Non-Small Cell Lung Cancer (NSCLC) (Market Leader ~86% share)
• Small Cell Lung Cancer (SCLC)
• Lung Carcinoid Tumors

➤ By Application

• Screening & Early Detection (Fastest Growing)
• Treatment Selection (Companion Diagnostics)
• Monitoring & Surveillance (MRD)

➤ By End-User

• Hospitals (Largest Segment)
• Diagnostic Laboratories (Fastest Growing)
• Specialty Cancer Centers

Conclusion

The lung cancer diagnostics market is entering an era of "Predictive Intelligence." Through 2036, success will be defined by diagnostic speed and precision. As the industry shifts from confirming the presence of cancer to predicting the effectiveness of specific immunotherapies, the companies that master AI-pathomics integration and liquid biopsy monitoring will be the leaders in the global fight against lung cancer.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=74159<ype=S

 About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com